According to the Zhitong Finance App, Baiyunshan (00874) issued an announcement. Recently, the company's branch Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (hereinafter referred to as “Baiyunshan Pharmaceutical General Factory”) received the “Proprietary Drug Registration Certificate” issued by the Macao Special Administrative Region Government Drug Administration.
Baiyunshan Pharmaceutical General Factory submitted a registration application for cephalexin capsules 0.125g to the Macao Special Administrative Region Government Drug Administration on June 1, 2026, which was pre-approved on June 22, 2026.
Cephalexin capsules are suitable for acute tonsillitis, angina, otitis media, sinusitis, bronchitis, pneumonia and other respiratory infections, urinary tract infections, and skin and soft tissue infections caused by sensitive bacteria. This medicine is an oral preparation and should not be used for severe infections.
According to data from the Mi Intranet, the sales volume of cefadroxil capsules in domestic cities, county-level public hospitals, cities, and online pharmacies in 2025 was RMB 24.72 million. Currently, the main manufacturers and sellers of cephalexin capsules in China include North China Pharmaceutical Hebei Huamin Pharmaceutical Co., Ltd., Hunan Colon Pharmaceutical Co., Ltd., and Shandong Luoxin Pharmaceutical Group Co., Ltd. In 2025, Baiyunshan Pharmaceutical General Factory's sales revenue of cephalexin capsules was RMB 4.5 million.
As of the date of this announcement, Baiyunshan Pharmaceutical General Factory has invested a total of about RMB 7.89 million (unaudited) in R&D expenses for this drug research and development project.